BR112016003030A2 - anticorpos iib do receptor anti-fc-gama e uso dos mesmos - Google Patents
anticorpos iib do receptor anti-fc-gama e uso dos mesmosInfo
- Publication number
- BR112016003030A2 BR112016003030A2 BR112016003030A BR112016003030A BR112016003030A2 BR 112016003030 A2 BR112016003030 A2 BR 112016003030A2 BR 112016003030 A BR112016003030 A BR 112016003030A BR 112016003030 A BR112016003030 A BR 112016003030A BR 112016003030 A2 BR112016003030 A2 BR 112016003030A2
- Authority
- BR
- Brazil
- Prior art keywords
- gamma receptor
- receptor iib
- antibodies
- iib antibodies
- fcibri
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
Abstract
a presente invenção refere-se a um anticorpo anti-fc¿riib que, em comparação com os anticorpos da técnica anterior, aumenta de forma marcante a fosforilação do itim de fc¿riib e pode assim ser utili-zado para o tratamento ou profilaxia de doenças autoimunes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13004094.2A EP2837637A1 (en) | 2013-08-16 | 2013-08-16 | Novel anti-FcyRIIB IgG-type antibody |
PCT/EP2014/002234 WO2015022077A1 (en) | 2013-08-16 | 2014-08-13 | Novel anti-fc-gamma receptor iib antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016003030A2 true BR112016003030A2 (pt) | 2017-09-12 |
Family
ID=49000296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016003030A BR112016003030A2 (pt) | 2013-08-16 | 2014-08-13 | anticorpos iib do receptor anti-fc-gama e uso dos mesmos |
Country Status (24)
Country | Link |
---|---|
US (1) | US10407499B2 (pt) |
EP (2) | EP2837637A1 (pt) |
JP (2) | JP6775420B2 (pt) |
KR (1) | KR102385790B1 (pt) |
CN (1) | CN105636987B (pt) |
AU (1) | AU2014308143B2 (pt) |
BR (1) | BR112016003030A2 (pt) |
CA (1) | CA2921251C (pt) |
CL (1) | CL2016000349A1 (pt) |
DK (1) | DK3033357T3 (pt) |
EA (1) | EA035855B1 (pt) |
ES (1) | ES2668482T3 (pt) |
HK (1) | HK1224302A1 (pt) |
HR (1) | HRP20180664T1 (pt) |
HU (1) | HUE038977T2 (pt) |
IL (1) | IL244135B (pt) |
MX (1) | MX2016002027A (pt) |
MY (1) | MY174711A (pt) |
NO (1) | NO3033357T3 (pt) |
PL (1) | PL3033357T3 (pt) |
PT (1) | PT3033357T (pt) |
SG (1) | SG11201600930RA (pt) |
SI (1) | SI3033357T1 (pt) |
WO (2) | WO2015022077A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
EP2837637A1 (en) * | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
KR102424169B1 (ko) | 2014-08-13 | 2022-07-25 | 수프레몰 게엠베하 | Fc 감마 수용체 iib 및 fc 입실론 수용체에 대한 신규 항체 |
US11576984B2 (en) * | 2018-03-26 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using |
US12030945B2 (en) | 2022-10-25 | 2024-07-09 | Seismic Therapeutic, Inc. | Variant IgG Fc polypeptides and uses thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6849719B2 (en) | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
DE10157290A1 (de) | 2001-11-22 | 2003-06-05 | Max Planck Gesellschaft | Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III |
WO2004016750A2 (en) * | 2002-08-14 | 2004-02-26 | Macrogenics, Inc. | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
AU2003265522A1 (en) * | 2003-08-18 | 2005-03-10 | Macrogenics, Inc. | FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
ATE519784T1 (de) | 2003-11-26 | 2011-08-15 | Max Planck Gesellschaft | An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz |
EP1747237A4 (en) * | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB-特异性抗体及其使用方法 |
CN1997667A (zh) * | 2004-05-10 | 2007-07-11 | 宏观基因有限公司 | 人源化FcγRⅡB特异性抗体及其使用方法 |
ES2359218T3 (es) | 2005-12-13 | 2011-05-19 | Suppremol Gmbh | POLIPÉPTIDOS Y POLIMÉRICOS PARA LOS RECEPTORES Fc. |
EP1870422A1 (en) | 2006-06-20 | 2007-12-26 | SuppreMol GmbH | Means for the treatment of diseases characterized by an excessive immune reaction |
MX2010005031A (es) | 2007-11-12 | 2010-06-25 | U3 Pharma Gmbh | Anticuerpos de axl. |
EP2234641B1 (en) * | 2008-01-03 | 2015-08-19 | Genmab A/S | Monoclonal antibodies against cd32b |
EP2313105B1 (en) | 2008-06-27 | 2013-07-24 | ZymoGenetics, Inc. | SOLUBLE HYBRID Fc gamma RECEPTORS AND RELATED METHODS |
US10669324B2 (en) | 2012-10-30 | 2020-06-02 | Suppremol Gmbh | Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein |
US10028998B2 (en) | 2012-10-30 | 2018-07-24 | Suppremol Gmbh | Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb |
EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
KR102424169B1 (ko) | 2014-08-13 | 2022-07-25 | 수프레몰 게엠베하 | Fc 감마 수용체 iib 및 fc 입실론 수용체에 대한 신규 항체 |
-
2013
- 2013-08-16 EP EP13004094.2A patent/EP2837637A1/en not_active Withdrawn
-
2014
- 2014-08-13 EP EP14755987.6A patent/EP3033357B1/en active Active
- 2014-08-13 KR KR1020167006840A patent/KR102385790B1/ko active IP Right Grant
- 2014-08-13 HU HUE14755987A patent/HUE038977T2/hu unknown
- 2014-08-13 NO NO14755987A patent/NO3033357T3/no unknown
- 2014-08-13 MX MX2016002027A patent/MX2016002027A/es active IP Right Grant
- 2014-08-13 SG SG11201600930RA patent/SG11201600930RA/en unknown
- 2014-08-13 EA EA201690383A patent/EA035855B1/ru not_active IP Right Cessation
- 2014-08-13 SI SI201430712T patent/SI3033357T1/en unknown
- 2014-08-13 CN CN201480057137.9A patent/CN105636987B/zh active Active
- 2014-08-13 JP JP2016533838A patent/JP6775420B2/ja active Active
- 2014-08-13 BR BR112016003030A patent/BR112016003030A2/pt not_active Application Discontinuation
- 2014-08-13 WO PCT/EP2014/002234 patent/WO2015022077A1/en active Application Filing
- 2014-08-13 MY MYPI2016700521A patent/MY174711A/en unknown
- 2014-08-13 CA CA2921251A patent/CA2921251C/en active Active
- 2014-08-13 PL PL14755987T patent/PL3033357T3/pl unknown
- 2014-08-13 DK DK14755987.6T patent/DK3033357T3/en active
- 2014-08-13 US US14/912,064 patent/US10407499B2/en active Active
- 2014-08-13 WO PCT/EP2014/002233 patent/WO2015022076A1/en active Application Filing
- 2014-08-13 PT PT147559876T patent/PT3033357T/pt unknown
- 2014-08-13 AU AU2014308143A patent/AU2014308143B2/en active Active
- 2014-08-13 ES ES14755987.6T patent/ES2668482T3/es active Active
-
2016
- 2016-02-15 IL IL244135A patent/IL244135B/en active IP Right Grant
- 2016-02-15 CL CL2016000349A patent/CL2016000349A1/es unknown
- 2016-10-27 HK HK16112372.5A patent/HK1224302A1/zh unknown
-
2018
- 2018-04-25 HR HRP20180664TT patent/HRP20180664T1/hr unknown
-
2019
- 2019-11-08 JP JP2019203264A patent/JP2020048562A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
BR112016024780A2 (pt) | composições e métodos relacionados com construtos de fc manipulados | |
CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
BR112019001570A2 (pt) | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 | |
GT201600215A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
BR112016000903A2 (pt) | anticorpos | |
CR20160199A (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
BR112018014016A2 (pt) | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer | |
BR112017000664A2 (pt) | anticorpo anti-pd-1 e seu uso | |
BR112017027549A2 (pt) | anticorpo para cd40 | |
BR112018010211A2 (pt) | formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab | |
BR112017011932A8 (pt) | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso | |
BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
BR112017008945A2 (pt) | Anticorpos anti-cs1 e conjugados fármaco- anticorpo | |
BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
BR112017002342A2 (pt) | novos anticorpos e usos dos mesmos | |
BR112015022260A8 (pt) | imunoterapia com tau | |
BR112017005522A2 (pt) | abas de aplicação heterogênea | |
EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
MX2020004674A (es) | Anticuerpos contra alfa-sinucleina y usos de los mismos. | |
BR112016025470A2 (pt) | ?hdl terapêutico? | |
BR112017012954A2 (pt) | composições e métodos para anticorpos que têm como alvo a bmp6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |